UCSF scientists are in a tight race against time, trying to spot telltale brain signals before a person’s first psychotic break. The idea is simple, even if the science is not: treat people while symptoms are still mild, instead of waiting for full-blown psychosis to crash in.
Using scalp EEG, researchers are zeroing in on a particular brain wave called the P300. It typically appears about 300 milliseconds after someone hears a distinct sound. In people who later develop schizophrenia, that P300 signal tends to be weaker. Paired with blood or spinal‑fluid biomarkers and targeted clinical trials, those signals could eventually help clinicians tailor early interventions instead of taking a wait‑and‑see approach.
How UCSF measures risk
At UCSF’s PATH program, director Dr. Daniel Mathalon and his team record P300 and other EEG signals in young people with concerning symptoms, then track who eventually converts to psychosis. According to UCSF News, high‑risk patients who later develop psychosis show reduced P300 amplitudes, and the program is enrolling participants in AMP‑SCZ trials that combine EEG testing with experimental treatments. Researchers hope those biomarkers will one day help clinicians decide who needs closer monitoring or earlier therapy.
How common is the risk
Schizophrenia affects roughly 1% of people worldwide, according to the World Health Organization. A broad review of psychosis‑risk studies found that about 15% of people at clinical high risk convert to a psychotic disorder within a year, roughly 20% by two years and about 25–30% by four years, a pattern summarized in a recent review on PMC. That means most people with early worrying symptoms will not progress to frank schizophrenia, although many who do not convert still struggle with mood, anxiety or cognitive problems.
Northwestern's spinal‑fluid breakthrough
Earlier this month, Northwestern researchers reported a cerebrospinal‑fluid biomarker, a freely circulating form of Cacna2d1, that was reduced in people with schizophrenia. They also tested a synthetic peptide, SEAD1, that repaired circuit dysfunction in mice. Northwestern Now reported that the discovery could help scientists match drugs to biological subgroups and speed up biomarker‑guided trials. The authors said the next steps include developing a blood test for selecting patients and continuing preclinical safety work.
What it means for treatment
Clinicians say reliable biomarkers could be a game‑changer for sorting out which high‑risk patients need aggressive intervention and which can be managed with therapy and symptom‑focused medications. As reported by the San Francisco Chronicle, most doctors avoid prescribing antipsychotics in the high‑risk group because of side effects and limited evidence that the drugs actually prevent schizophrenia. Instead, they tend to emphasize psychotherapy and medications that target anxiety or depression. For patients who do go on to develop psychosis, however, clinicians say early antipsychotic treatment is linked with better long‑term outcomes.
Where people can turn
Across the Bay Area, specialty clinics offer coordinated care and research opportunities for people with early psychotic symptoms. Stanford’s INSPIRE clinic is one such model, pairing psychotherapy, family education and medication management with participation in studies, according to Stanford Medicine. Programs like these lean heavily on outreach, since most conversions, when they happen at all, occur in the first year or two after symptoms begin.
Caveats and next steps
Researchers are quick to stress that these biomarkers are not ready for prime‑time clinical use. They need to be validated in diverse populations, and false positives could expose people to unnecessary or unwanted treatments. UCSF leaders emphasize weighing the potential benefits of earlier intervention against the real risk of overtreatment. At the same time, Northwestern Now notes that the peptide study offers a proof‑of‑concept for a biomarker‑linked therapy, if its findings eventually translate to humans. For now, scientists say that combining EEG, fluid biomarkers and carefully designed trials offers a cautious but realistic path toward changing how psychosis is prevented and treated.
